Document is current

Article History

Received: 31 May 2023

Accepted: 22 August 2023

First Online: 9 September 2023

Declarations

:

: Ashraf Alzaabi and Hao-Chien Wang have no conflicts to declare. John P Bell, Nigel Budgen, Hisham Farouk and Ekaterina Maslova are employees of AstraZeneca and own stock in AstraZeneca. Felicia Montero-Arias has been a part of clinical studies sponsored by AstraZeneca, Novartis, NIH and Moderna; has received advisory board fees from AstraZeneca, Novartis and Roche; and has received payment for speaking engagements from AstraZeneca, Novartis and GlaxoSmithKline. David B. Price has a board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme and Thermo Fisher; has consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc., Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; has received grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; has received payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme; has received payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis and Thermo Fisher; has stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); has a 5% shareholding in Timestamp, which develops an adherence monitoring technology; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. David J. Jackson has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Sanofi, Boehringer Ingelheim and Chiesi and research grants from AstraZeneca.

: This study was conducted in compliance with the Declaration of Helsinki.

: IQVIA did not provide any support for the analysis or interpretation of the data. The statements, findings, conclusions, views and opinions contained and expressed in this article are based, in part, on data obtained under licence from the following IQVIA Ltd information service: IQVIA MIDAS inhaler sales data across all respiratory conditions (2018–2019) in 28 countries, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. These statements, findings, conclusions, views and opinions are not necessarily those of IQVIA Ltd or any of its affiliated or subsidiary entities.